Treating Anemia Earlier in Myelodysplastic Syndromes

Therapies With Different Mechanisms of Action Available for Low-Risk MDS

Bertrand Y. Tuan, MD, discusses the therapies relevant to patients with low-risk myelodysplastic syndrome.

Ring Sideroblasts Status Affects Treatment Decisions for Frontline MDS

Amer Zeidan, MBBS, discusses how ring sideroblasts status affects using luspatercept in patients with myelodysplastic syndromes.

COMMANDS Trial Demonstrates Benefit Across Mutations in RS-Positive LR-MDS

During a Case-Based Roundtable® event, Yazan Madanat, MD, discussed a the patient population and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.

Genetics and Ring Sideroblasts Impact ESA-Refractory Anemia in MDS

During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case of myelodysplastic syndrome first treated with erythropoiesis-stimulating agent in the second article of a 2-part series.

Luspatercept in MDS Promotes Transfusion Independence and Anemia Response

During a Case-Based Roundtable® event, Azra Raza, MD, discussed a patient case and outcomes of the COMMANDS trial of luspatercept in myelodysplastic syndrome in the first article of a 2-part series.

COMMANDS Trial Shows Positive Result in MDS Despite Pandemic

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, reviewed data for luspatercept-aamt for patients with low-risk myelodysplastic syndrome in the second article of a 2-part series.

Zeidan Reviews Past Treatment Options for Patient With Lower-Risk MDS

During a Case-Based Roundtable® event, Amer Zeidan, MBBS, discussed how he would have approached a patient with anemia from low-risk myelodysplastic syndrome before the development of newer drugs in the first article of a 2-part series.

Luspatercept Shows Clinically Meaningful Improvement Over ESAs in MDS

Guillermo Garcia-Manero, MD, discusses the design and outcomes of the phase 3 COMMANDS trial in patients with low-risk myelodysplastic syndromes.

Subgroup Analyses of COMMANDS Trial Favor Luspatercept in MDS

Amer Zeidan, MBBS, discusses the primary end point and subgroup analyses performed on the COMMANDS trial of luspatercept-amt for treating anemia in patients with myelodysplastic syndromes.

How the Frontline Indication for Luspatercept Impacts Anemia in MDS

Amer Zeidan, MBBS, discusses the recent expansion of the indication for luspatercept-amt to the frontline setting to treat anemia in patients with lower-risk myelodysplastic syndromes.